NeoGenomics, Inc.
NEO scores 24.2 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Minor adjustments (-2.0 points) applied. NEO's rank of #1209 primarily reflects its factor profile relative to the conservative weight vector.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| NEO | 24.2 | N/A | 10.1% | -14.9% | $257M |
| INCY | 89.9 | 15.8 | 21.2% | 25.0% | $20.2B |
| GMAB | 86.1 | 13.1 | 22.8% | 36.4% | $18.1B |
| CPRX | 83.7 | 13.7 | 23.5% | 37.6% | $2.9B |
| ASND | 78.3 | 16.6 | 98.0% | -31.7% | $14.0B |
| EXEL | 78.3 | 15.1 | 7.0% | 33.7% | $11.9B |
| VRTX | 78.2 | 32.1 | 8.9% | 32.9% | $125.2B |
| NBIX | 75.1 | 26.5 | 21.4% | 16.7% | $13.3B |
| RPRX | 75.0 | 25.1 | 5.1% | 32.4% | $19.8B |
| HOLX | 74.8 | 31.1 | 1.7% | 13.8% | $16.8B |
| AMGN | 74.2 | 26.0 | 10.0% | 21.0% | $210.2B |
| ARGX | 73.7 | 35.1 | 78.6% | 38.0% | $48.0B |
| REGN | 73.0 | 19.4 | 1.0% | 31.4% | $81.3B |
| ALKS | 72.9 | 16.5 | -6.4% | 23.9% | $5.0B |
| ISRG | 72.7 | 61.7 | 20.5% | 28.4% | $177.8B |
| KRYS | 71.5 | 41.4 | 473.0% | 30.7% | $8.0B |
| Sector Average | 36.6 | 41.9 | 161.5% | -3292.7% | โ |
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Stock is in an uptrend above the 200-day moving average. This is the stage where institutional accumulation typically occurs. The 50-day SMA provides support.
Stage 2 uptrend โ institutional accumulation phase. SMA50 pullbacks are the highest-probability entry points. Stop below SMA200 preserves capital if trend breaks.
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Revenue | $190M | $188M | $181M | $168M |
| Gross Profit | $76M | $80M | $77M | $73M |
| Operating Income | $-11M | $-27M | $-48M | $-28M |
| Net Income | $-10M | $-27M | $-45M | $-26M |
| EPS (Diluted) | $-0.38 | $-1.05 | $-1.75 | $-1.00 |
| Gross Margin | 39.8% | 42.8% | 42.6% | 43.6% |
| Operating Margin | -5.9% | -14.4% | -26.3% | -16.6% |
| Net Margin | -5.2% | -14.4% | -24.9% | -15.4% |
| Year | Low | High | Range | Status |
|---|---|---|---|---|
| 2021 | $29.66 | $55.97 | 61.5% | Wide |
| 2022 | $6.00 | $35.34 | 141.9% | Wide |
| 2023 | $8.71 | $21.22 | 83.6% | Wide |
| 2024 | $12.77 | $19.00 | 39.2% | Wide |
| 2025 | $4.72 | $19.11 | 120.8% | Wide |
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.